INOVIO's VGX-3100 second Phase 3 trial is fully enrolled. VGX-3100 is a designed DNA medicine to help protect people from infectious diseases and treat cancer and HPV-associated diseases.

This Phase 3 prospective, randomized, double-blind, placebo-controlled study of VGX-3100 delivered intramuscularly (IM) followed by electroporation (EP) delivered with CELLECTRA™ 5PSP in adult women with histologically confirmed high-grade squamous intraepithelial lesions (HSIL) (cervical intraepithelial neoplasia grade 2 [CIN2] or grade 3 [CIN3]) of the cervix, associated with HPV-16 and/or HPV-18.

This trial began in April 2019 and is expected to publish results in 2022. 198 women are enrolled in this study.